All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Proteasome inhibitors
Proteasome inhibitors
Proteasome inhibitors bind to the proteasome and prevent degradation of proteins involved in various signaling cascades. Preclinical studies in AML indicate proteasome inhibition disrupts proliferative cell signaling pathways, has cytotoxic synergism with other chemotherapies, and induces autophagy. For example, in AML, bortezomib is being investigated with combination chemotherapy regimens.